Steglujan FDA Approval History
FDA Approved: Yes (First approved December 19, 2017)
Brand name: Steglujan
Generic name: ertugliflozin and sitagliptin
Dosage form: Tablets
Company: Merck
Treatment for: Diabetes, Type 2
Steglujan (ertugliflozin and sitagliptin) is a sodium glucose co-transporter 2 (SGLT2) inhibitor, and dipeptidyl peptidase-4 (DPP-4) inhibitor combination used to improve glycemic control in adults with type 2 diabetes.
Development timeline for Steglujan
| Date | Article |
|---|---|
| Dec 22, 2017 | Approval FDA Approves Steglujan (ertugliflozin and sitagliptin) for Type 2 Diabetes |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
